AU2003273300A1 - Modified glp-1 receptor agonists and their pharmacological methods of use - Google Patents

Modified glp-1 receptor agonists and their pharmacological methods of use

Info

Publication number
AU2003273300A1
AU2003273300A1 AU2003273300A AU2003273300A AU2003273300A1 AU 2003273300 A1 AU2003273300 A1 AU 2003273300A1 AU 2003273300 A AU2003273300 A AU 2003273300A AU 2003273300 A AU2003273300 A AU 2003273300A AU 2003273300 A1 AU2003273300 A1 AU 2003273300A1
Authority
AU
Australia
Prior art keywords
receptor agonists
pharmacological methods
modified glp
glp
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003273300A
Other versions
AU2003273300A8 (en
Inventor
Clark Pan
James P. Whelan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of AU2003273300A1 publication Critical patent/AU2003273300A1/en
Publication of AU2003273300A8 publication Critical patent/AU2003273300A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003273300A 2002-09-06 2003-09-04 Modified glp-1 receptor agonists and their pharmacological methods of use Abandoned AU2003273300A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40869602P 2002-09-06 2002-09-06
US60/408,696 2002-09-06
US43936903P 2003-01-09 2003-01-09
US60/439,369 2003-01-09
PCT/US2003/028093 WO2004022004A2 (en) 2002-09-06 2003-09-04 Modified glp-1 receptor agonists and their pharmacological methods of use

Publications (2)

Publication Number Publication Date
AU2003273300A1 true AU2003273300A1 (en) 2004-03-29
AU2003273300A8 AU2003273300A8 (en) 2004-03-29

Family

ID=31981605

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003273300A Abandoned AU2003273300A1 (en) 2002-09-06 2003-09-04 Modified glp-1 receptor agonists and their pharmacological methods of use

Country Status (5)

Country Link
EP (1) EP1539210A4 (en)
JP (1) JP2006501820A (en)
AU (1) AU2003273300A1 (en)
CA (1) CA2497794A1 (en)
WO (1) WO2004022004A2 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
EP1478406B1 (en) 2002-02-27 2011-01-05 PharmaIN Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
ES2420581T3 (en) 2003-03-14 2013-08-26 Biogenerix Gmbh Branched water soluble polymers and their conjugates
CN1832959A (en) 2003-03-19 2006-09-13 伊莱利利公司 Polyethelene glycol link glp-1 compounds
EP1608680A2 (en) * 2003-03-24 2005-12-28 Novo Nordisk A/S Glp-2 derivatives
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
MXPA05010773A (en) 2003-04-09 2005-12-12 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods.
ATE540055T1 (en) 2003-05-09 2012-01-15 Biogenerix Ag COMPOSITIONS AND METHODS FOR PRODUCING HUMAN GROWTH HORMONE GLYCOSYLATION MUTANTS
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
BRPI0417717A (en) 2003-12-18 2007-04-03 Novo Nordisk As compound, pharmaceutical composition, and use of a compound
WO2005070138A2 (en) 2004-01-08 2005-08-04 Neose Technologies, Inc. O-linked glycosylation of peptides
CN101001639A (en) * 2004-06-12 2007-07-18 拜尔药品公司 Pegylation of vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase activating peptide (PACAP) receptor 2 (VPAC2) agonists and methods of use
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
JP4951527B2 (en) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー GlycoPEGylated granulocyte colony stimulating factor
EP1845105A4 (en) * 2005-01-14 2009-02-18 Wuxi Grandchamp Pharmaceutical Modified exendins and uses thereof
US8716221B2 (en) 2005-01-14 2014-05-06 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1883419A4 (en) * 2005-05-06 2010-08-04 Bayer Pharmaceuticals Corp Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1767545B1 (en) 2005-09-22 2009-11-11 Biocompatibles UK Limited GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
US8759290B2 (en) * 2005-10-18 2014-06-24 Biocon Limited Oral glucagon-like peptide conjugates for metabolic diseases
US20090286724A1 (en) * 2005-10-26 2009-11-19 Chugai Seiyaku Kabushiki Kaisha Aggregable glp-1 analogue and sustained-release pharmaceutical composition
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP2570133B1 (en) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
EP2364735A3 (en) 2005-12-16 2012-04-11 Nektar Therapeutics Branched PEG conjugates of GLP-1
KR101529318B1 (en) 2005-12-19 2015-06-16 파마인 코포레이션 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
EP2573111A1 (en) 2006-04-20 2013-03-27 Amgen Inc. GLP-1 compounds
EP1854455B1 (en) * 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
KR100886783B1 (en) 2006-06-12 2009-03-04 성균관대학교산학협력단 N-terminal modified PEG-TRAIL, method for preparing and uses thereof
CA2787343C (en) 2006-06-26 2016-08-02 Amgen Inc. Compositions comprising modified lcat and uses thereof
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (en) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス Purification method for polypeptide conjugates
CN101125207B (en) * 2006-11-14 2012-09-05 上海华谊生物技术有限公司 Exendin or its analogs with polyethylene group and its preparation and application
US8669228B2 (en) 2007-01-05 2014-03-11 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
KR20150116465A (en) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon/glp-1 receptor co-agonists
EP2144923B1 (en) 2007-04-03 2013-02-13 BioGeneriX AG Methods of treatment using glycopegylated g-csf
GB2448895A (en) * 2007-05-01 2008-11-05 Activotec Spp Ltd GLP-1 like compounds and uses thereof
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
WO2009058662A2 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
CN101965200B (en) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 Conjugated factor VIII molecules
JP5775450B2 (en) 2008-06-17 2015-09-09 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon / GLP-1 receptor co-agonist
BRPI0915282A2 (en) 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp gip-based mixed agonists for the treatment of metabolic disorders and obesity
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (en) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション Novel cyclic benzimidazole derivatives useful as antidiabetic agents
TWI489992B (en) 2008-12-19 2015-07-01 印地安那大學研究及技術公司 Amide based glucagon superfamily peptide prodrugs
AU2010242422B2 (en) * 2009-03-26 2014-12-04 The Hong Kong Polytechnic University Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
US9382525B2 (en) * 2009-03-26 2016-07-05 The Hong Kong Polytechnic University Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
IN2012DN00377A (en) 2009-06-16 2015-08-21 Univ Indiana Res & Tech Corp
RU2537239C2 (en) * 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Pharmaceutical composition containing agonist glp-1, insulin and methionine
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2359843A1 (en) * 2010-01-21 2011-08-24 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
MX2012013001A (en) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting nuclear hormone receptor activity.
CN103179976A (en) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
CN103179979A (en) 2010-06-24 2013-06-26 印第安纳大学研究及科技有限公司 Amide based glucagon superfamily peptide prodrugs
US20130137645A1 (en) * 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
SG191194A1 (en) 2010-12-22 2013-07-31 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
KR20140043793A (en) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon/glp-1 receptor co-agonists
US20140221283A1 (en) 2011-06-22 2014-08-07 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
KR101357117B1 (en) * 2011-06-28 2014-02-06 비앤엘델리팜 주식회사 PEGylated Exendin-4 analogues or its derivatives, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes
KR20140049588A (en) * 2011-08-08 2014-04-25 투 투 바이오테크 리미티드 Novel peptides, compositions comprising the same and uses thereof in methods for the treatment of metabolic, cardiac and immune-related disorders
JP6324315B2 (en) 2011-11-17 2018-05-16 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon superfamily of peptides exhibiting glucocorticoid receptor activity
CN104583232B (en) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 Show the glucagon analogs of GIP receptor actives
RU2015106909A (en) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. ANTI-DIABETIC TRICYCLIC COMPOUNDS
TWI674270B (en) 2012-12-11 2019-10-11 英商梅迪繆思有限公司 Glucagon and glp-1 co-agonists for the treatment of obesity
CA2898482A1 (en) 2013-02-22 2014-08-28 Linda L. Brockunier Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014140222A1 (en) * 2013-03-14 2014-09-18 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
KR20180015131A (en) 2015-06-04 2018-02-12 안트리아바이오 인크. Amine Pegylation Methods for the Preparation of Site-Specific Protein Conjugates
TWI726889B (en) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 Protease-resistant lipidated peptides
WO2017106627A1 (en) 2015-12-17 2017-06-22 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
DK3393496T3 (en) 2015-12-23 2023-11-13 Univ Johns Hopkins Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
JP7017248B2 (en) * 2016-03-16 2022-02-08 プロリンクス エルエルシー Sustained release conjugate of exenatide analogs
US11084879B2 (en) 2016-04-07 2021-08-10 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
KR102193211B1 (en) * 2019-11-27 2020-12-18 (주)디앤디파마텍 biotin derivative-conjugated polypeptide and pharmaceutical composition for oral administration comprising the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423034A (en) * 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
EP0512042B1 (en) * 1990-01-24 1998-04-08 BUCKLEY, Douglas I. Glp-1 analogs useful for diabetes treatment
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ATE138102T1 (en) * 1991-02-19 1996-06-15 Takeda Chemical Industries Ltd METHOD FOR PRODUCING CYSTEIN-FREE PEPTIDES
EP0796335A1 (en) * 1994-12-07 1997-09-24 Bionebraska, Inc. Production of peptides using recombinant fusion protein constructs
AU2610899A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
EP1267912A2 (en) * 2000-03-14 2003-01-02 Burkhard Göke Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
AR036711A1 (en) * 2001-10-05 2004-09-29 Bayer Corp PEPTIDES THAT ACT AS GLON-RECEPTOR AGONISTS AND AS GLUCAGON RECEPTOR ANTAGONISTS AND THEIR PHARMACOLOGICAL USE METHODS

Also Published As

Publication number Publication date
JP2006501820A (en) 2006-01-19
AU2003273300A8 (en) 2004-03-29
EP1539210A2 (en) 2005-06-15
WO2004022004A2 (en) 2004-03-18
WO2004022004A3 (en) 2004-12-23
CA2497794A1 (en) 2004-03-18
EP1539210A4 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
AU2003273300A1 (en) Modified glp-1 receptor agonists and their pharmacological methods of use
IL160706A0 (en) Peptides acting as both glp-1 receptor agonists and their pharmacological methods of use
EP1883419A4 (en) Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
AU2003261723A1 (en) Cxcr4 antagonist and use thereof
AU2003275311A1 (en) Solid micro-perforators and methods of use
AU2003225903A1 (en) Methods of using farnesoid x receptor (fxr) agonists
AU2003221683A1 (en) Thermal interface materials and methods for their preparation and use
EP1583503A4 (en) Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
PL377777A1 (en) Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
IL176223A0 (en) The glucagon-like peptide-1 receptor agonists, the preparation and the use of the same
AU4134101A (en) Hormone receptor functional entities and methods of their use
IL163613A0 (en) Partial and full agonists of a1 adenosine receptors
AU2003301216A1 (en) Novel use of liver x receptor agonists
AU2003223653A1 (en) Partial and full agonists of a1 adenosine receptors
AU2002351175A1 (en) Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
AU6503900A (en) Chemokine receptor antagonists and methods of use therefor
AU2003280675A1 (en) SELECTIVE HUMAN Beta3 ADRENALIN RECEPTOR AGONIST AGENT
AU5861900A (en) Receptor agonists and antagonists
AU2003287802A1 (en) Palpometer and methods of use thereof
AU6389900A (en) Chemokine receptor antagonists and methods of use therefor
AU2003247052A1 (en) Mcp-1 receptor antagonists and method of use thereof
AU2003210062A1 (en) Agonists and antagonists of gonadotropin-releasing hormone-2, and use thereof
AU2003248352A1 (en) PROCESSES AND INTERMEDIATES USEFUL IN PREPARING Beta3-ADRENERGIC RECEPTOR AGONISTS
AU2003300122A1 (en) Agonists and antagonists of the human odorant receptor or17-4 and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase